Brainsway, having won FDA clearance at the beginning of the year for its Deep TMS (transcranial magnetic stimulation) system as a treatment option for drug resistant major depressive disorder, is about to begin shipments of its device in the U.S. Deep TMS sets ups highly focused magnetic fields within a special helmet to target specific regions of the brain. In Europe, besides depression treatment, the system is also approved for addressing neuropathic chronic pain, bi-polar disorder, and schizophrenia and is being investigated for conditions such as Parkinson’s, PTSD, and as an aid in quitting smoking.

Treatment is conducted in an outpatient setting during 20-minute sessions over a four week period. Moreover, no sedation is required during treatment sessions and clinical trials haven’t detected any significant long term side effects.